Drug Trial Radar · NCT06093542
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
Last checked: Nov 20, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Oct 25, 2023
Primary completion
Mar 20, 2024
Study completion Mar 20, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will evaluate the safety, tolerability, and the pharmacokinetics (PK) of AZD7503 following multiple subcutaneous doses in healthy Japanese participants.
Conditions
- Heathy Participants
Interventions
AZD7053Drug
Randomised participants will receive AZD7503 subcutaneously.
PlaceboDrug
Randomised participants will receive placebo subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: From Screening (Day -28) until Follow-up Day 127 (10 weeks post last dose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Sumida-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.